Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Kymera Therapeutics Q3 2026 Results: Net Loss of $132M, Loss Widens

Kymera Therapeutics reported collaboration revenue of $99.4 million for the nine months ended September 30, 2026, a significant increase from $36.3 million in the prior year. Despite this, the company recorded a net loss of $262.4$ million for the period due to rising research and development expenses, which reached $346.2 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.02.8
Net income-132.0-82.2
EPS (diluted, $ a share)$-1.32$-0.94

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: KYMR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Kymera Therapeutics, Inc.: key numbers

Share price
$125.85Close, Nov 16
Market cap
$10.7B
Shares outstanding
85.37MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Kymera Therapeutics, Inc.

All →
7:11 AM ET 8-K
Financial Results

Kymera Therapeutics Financial Results

Kymera Therapeutics reported financial results for the third quarter ended September 30, 2026, and announced positive Phase 1 data for its IRF5 degrader, KT-579. The company remains well-capitalized with $1.6 billion in cash, providing a runway into 2029, and expects topline Phase 2b data for its STAT6 degrader, KT-621, by year-end 2026.

Term
Q3 2026

“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology. With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape.”

Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics

“The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways through a single oral mechanism.”

Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics
5:20 PM ET Form 4
Insider Selling

Kymera Therapeutics CEO Nello Mainolfi Sells $3.41M of Stock

Nello Mainolfi, CEO, sold 30,000 shares of Kymera Therapeutics, Inc. at $111.44 to $116.12 a share (average $113.80) in 6 transactions, worth $3.41M in total on Oct 1, 2026. Shares held after the trade: 666,568 (-0.0%).

Value
$3.41M
Shares
30,000
Average price
$113.80
Role
CEO
Holding change
-0.0%
Trade date
Oct 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.